Specifically, we show that PRI-724, a potent inhibitor of β-catenin/CBP interactions, sensitizes HCC cells to sorafenib, overcoming resistance and significantly reducing tumor growth in vitro and in preclinical models. Here, CREBBP is linked to neoplasm.